慢性粒单核细胞白血病中RAS通路突变的谱系及临床病理特征
该研究纳入814例慢性粒单核细胞白血病(CMML)患者,评估RAS通路(RASp)突变的谱系、克隆结构及临床意义,在342例(42%)中检出461个RASp突变。RASp突变与较短的总生存期(HR 1.55;95%CI 1.15-2.07;P=.0075)和无白血病生存期(HR 1.67;95%CI 1.26-2.20;P=.0011)相关,并影响骨髓增生异常型及TET2突变型CMML的结局。
要点
- 342/814例(42%)CMML患者携带RASp突变,共检出461个突变。
- RASp突变者总生存期较短(HR 1.55;95%CI 1.15-2.07;P=.0075)。
- RASp突变者无白血病生存期较短(HR 1.67;95%CI 1.26-2.20;P=.0011)。
核心结论
- RASp突变预测CMML患者总生存期和无白血病生存期较短,并影响骨髓增生异常型及TET2突变型CMML的结局。
- 作者认为这些数据为CMML的精细基因组分类奠定基础,并强调需要开发针对RAS的治疗。
- RASp突变可与IDH2和RUNX1突变协同导致无白血病生存期缩短。
研究设计与样本
- 研究纳入814例CMML患者队列,评估RASp突变的谱系、克隆结构及意义。
- 在342例患者(42%)中鉴定出461个RASp突变。
主要发现
- N/KRAS与CBL突变最常见,分别常累及P-loop或RING结构域,并常作为优势事件出现(分别为63%和65%)。
- BRAF、NF1和PTPN11突变分布于整个基因结构,并常作为亚克隆事件出现(分别为75%、64%和59%)。
- CBL突变常与SRSF2及双打击TET2共显性出现,并富集KIT突变。
- PTPN11突变更多与SETBP1和DNMT3A突变共存,与TET2或ASXL1共显性少见。
- RASp突变预测总生存期较短(HR 1.55;95%CI 1.15-2.07;P=.0075)和无白血病生存期较短(HR 1.67;95%CI 1.26-2.20;P=.0011)。
临床怎么用
- 作者认为这些数据为CMML的精细基因组分类奠定基础。
- 作者强调需要为CMML患者开发针对RAS的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RAS pathway (RASp) mutations induce proliferative features, and promote transformation in chronic myelomonocytic leukemia (CMML). However, the unique clonal landscape and hierarchy of distinct RASp mutations remain unexplored. To characterize the landscape, architecture, and implications of unique RASp mutations in CMML, we evaluated a cohort of 814 patients with CMML. We identified 461 RASp mutations among 342 patients (42%). N/KRAS and CBL mutations were the most common, frequently involved the P-loop or RING domains, respectively, and frequently appeared as dominant events (63% and 65%, respectively). BRAF, NF1, and PTPN11 mutations spanned throughout the gene structure, and frequently appeared as subclonal events (75%, 64%, and 59%, respectively). CBL mutations frequently occurred in codominance with SRSF2 and multihit TET2, and were enriched for KIT mutations. PTPN11 mutations more frequently co-occurred with SETBP1 and DNMT3A mutations, and were infrequently codominant with TET2 or ASXL1. RASp mutations predicted for shorter overall survival (hazard ratio [HR], 1.55; 95% confidence interval [CI], 1.15-2.07; P = .0075) and leukemia-free survival (LFS; HR, 1.67; 95% CI, 1.26-2.20; P = .0011), influenced outcomes of myelodysplastic and TET2 mutant CMML, and cooperated with IDH2 and RUNX1 mutations to induce shorter LFS. These data set the bases for refined genomic classifications of CMML, and underscore the need to develop RAS-directed therapies for patients with CMML.
引用
- Montalban-Bravo G, Loghavi S, Li Z, et al. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. Blood Adv. 2025. PMID: 40644618. doi:10.1182/bloodadvances.2025016529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。